ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Rassi A Jr., Rassi A, Marin-Neto JA, 2010. Chagas disease. Lancet 375: 1388–1402.
-
2.
Marcus R, Henao-Martínez AF, Nolan M, Livingston E, Klotz SA, Gilman RH, Miranda-Schaeubinger M, Meymandi S, 2021. Recognition and screening for chagas disease in the USA. Ther Adv Infect Dis 8: 20499361211046086.
-
3.
Irish A, Whitman JD, Clark EH, Marcus R, Bern C, 2022. Updated estimates and mapping for prevalence of Chagas disease among adults, United States. Emerg Infect Dis 28: 1313–1320.
-
4.
Zamora LE, Palacio F, Kozlowski DS, Doraivelu K, Dude CM, Jamieson DJ, Haddad LB, 2020. Chagas disease screening using point-of-care testing in an at-risk obstetric population. Am J Trop Med Hyg 104: 959–963.
-
5.
Hyson P et al., 2021. Experiences with diagnosis and treatment of Chagas disease at a United States teaching hospital–clinical features of patients with positive screening serologic testing. Trop Med Infect Dis 6: 93.
-
6.
Park S, Sanchez DR, Traina MI, Bradfield JS, Hernandez S, Ufion AJA, Dufani J, Bergin P, Wachsner RY, Meymandi SK, 2017. The prevalence of Chagas disease among Latin American immigrants with pacemakers in Los Angeles, California. Am J Trop Med Hyg 96: 1139–1142.
-
7.
Meymandi SK, Forsyth CJ, Soverow J, Hernandez S, Sanchez D, Montgomery SP, Traina M, 2017. Prevalence of Chagas disease in the Latin American-born population of Los Angeles. Clin Infect Dis 64: 1182–1188.
-
8.
Traina MI et al., 2017. Prevalence of Chagas disease in a U.S. population of Latin American immigrants with conduction abnormalities on electrocardiogram. PLoS Negl Trop Dis 11: e0005244.
-
9.
Chadalawada S et al., 2020. Risk of chronic cardiomyopathy among patients with the acute phase or indeterminate form of Chagas disease: a systematic review and meta-analysis. JAMA Netw Open 3: e2015072.
-
10.
Chadalawada S et al., 2021. Mortality risk in chronic Chagas cardiomyopathy: a systematic review and meta-analysis. ESC Heart Fail 8: 5466–5481.
-
11.
Vargas Barahona L et al., 2023. Previous corticosteroid exposure associates with an increased Pneumocystis jirovecii pneumonia mortality among HIV-negative patients: a global research network with a follow-up multicenter case-control study. Ther Adv Infect Dis 10: 20499361231159481.
-
12.
Chastain DB, Motoa G, Ortiz-Martínez Y, Gharamti A, Henao-Martínez AF, 2023. Characteristics and clinical manifestations of monkeypox among people with and without HIV in the United States: a retrospective cohort. AIDS 37: 611–616.
-
13.
Kennis M et al., 2022. Seasonal variations and risk factors of Streptococcus pyogenes infection: a multicenter research network study. Ther Adv Infect Dis 9: 20499361221132101.
-
14.
GovInfo The Health Insurance Portability and Accountability Act of 1996. Public Law 104–191. Available at: https://www.govinfo.gov/app/details/PLAW-104publ191. Accessed August 18, 2023.
-
15.
World Health Organization , 2018. Guidelines for the Diagnosis and Treatment of Chagas Disease. Available at: https://www.who.int/publications/i/item/9789275120439. Accessed July 19, 2023.
-
16.
Pentima MCD, Hwang L-Y, Skeeter CM, Edwards MS, 1999. Prevalence of antibody to Trypanosoma cruzi in pregnant Hispanic women in Houston. Clin Infect Dis 28: 1281–1285.
-
17.
Leiby DA, Herron RM Jr., Read EJ, Lenes BA, Stumpf RJ, 2002. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 42: 549–555.
-
18.
Centers for Disease Control and Prevention , 2007. Blood donor screening for Chagas disease – United States, 2006–2007. MMWR Morb Mortal Wkly Rep 56: 141–143.
-
19.
Hasslocher-Moreno AM, Xavier SS, Saraiva RM, de Sousa AS, 2021. Indeterminate form of Chagas disease: historical, conceptual, clinical, and prognostic aspects. Rev Soc Bras Med Trop 54: e02542021.
-
20.
Rabelo DR, da Costa Rocha MO, de Barros MVL, da Silva JLP, Tan TC, Nunes MCP, 2014. Impaired coronary flow reserve in patients with indeterminate form of Chagas’ disease. Echocardiography 31: 67–73.
-
21.
Olivo Freites C, Sy H, Gharamti A, Higuita NIA, Franco-Paredes C, Suárez JA, Henao-Martínez AF, 2022. Chronic Chagas disease – the potential role of reinfections in cardiomyopathy pathogenesis. Curr Heart Fail Rep 19: 279–289.
-
22.
Moreira HT, Volpe GJ, Mesquita GM, Braggion-Santos MF, Pazin-Filho A, Marin-Neto JA, Schmidt A, 2022. Association of left ventricular abnormalities with incident cerebrovascular events and sources of thromboembolism in patients with chronic Chagas cardiomyopathy. J Cardiovasc Magn Reson 24: 52.
-
23.
Healy C, Viles-Gonzalez JF, Sáenz LC, Soto M, Ramírez JD, d’Avila A, 2015. Arrhythmias in chagasic cardiomyopathy. Card Electrophysiol Clin 7: 251–268.
-
24.
Singh A, Cohen B, Sturzoiu T, Vallabhaneni S, Shirani J, 2020. Recent trends in hospital admissions and outcomes of cardiac Chagas disease in the United States. Int J Crit Illn Inj Sci 10: 134–139.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 6027 | 1815 | 144 |
| Full Text Views | 391 | 91 | 2 |
| PDF Downloads | 239 | 73 | 0 |
Clinical Characteristics and Outcomes of Chagas Disease in the United States: A Multicenter Retrospective Analysis
Andrés F. Henao-Martínez
Andrés F. Henao-Martínez
Division of Infectious Diseases, Department of Medicine, University of Colorado Denver, Aurora, Colorado;
Search for other papers by Andrés F. Henao-Martínez in
Current site
Google Scholar
PubMed
Search for other papers by Andrés F. Henao-Martínez in
Current site
Google Scholar
PubMed
Christian Olivo-Freites
Christian Olivo-Freites
Ryan Health, Infectious Diseases, New York, New York;
Search for other papers by Christian Olivo-Freites in
Current site
Google Scholar
PubMed
Search for other papers by Christian Olivo-Freites in
Current site
Google Scholar
PubMed
Nelson I. Agudelo Higuita
Nelson I. Agudelo Higuita
Department of Medicine, Section of Infectious Diseases, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma;
Instituto de Enfermedades Infecciosas y Parasitología Antonio Vidal, Tegucigalpa, Honduras;
Search for other papers by Nelson I. Agudelo Higuita in
Current site
Google Scholar
PubMed
Instituto de Enfermedades Infecciosas y Parasitología Antonio Vidal, Tegucigalpa, Honduras;
Search for other papers by Nelson I. Agudelo Higuita in
Current site
Google Scholar
PubMed
Carolina Ferraz
Carolina Ferraz
Division of Infectious Diseases, Department of Medicine, University of Colorado Denver, Aurora, Colorado;
Search for other papers by Carolina Ferraz in
Current site
Google Scholar
PubMed
Search for other papers by Carolina Ferraz in
Current site
Google Scholar
PubMed
Carlos Franco-Paredes
Carlos Franco-Paredes
Hospital Infantil de México, Ciudad de México, Mexico;
Instituto Conmemorativo Gorgas de Estudios de la Salud, Panama City, Panama;
Search for other papers by Carlos Franco-Paredes in
Current site
Google Scholar
PubMed
Instituto Conmemorativo Gorgas de Estudios de la Salud, Panama City, Panama;
Search for other papers by Carlos Franco-Paredes in
Current site
Google Scholar
PubMed
Jose Tuells
Jose Tuells
Department of Community Nursing, Preventive Medicine and Public Health and History of Science, University of Alicante, Alicante, Spain;
Search for other papers by Jose Tuells in
Current site
Google Scholar
PubMed
Search for other papers by Jose Tuells in
Current site
Google Scholar
PubMed
Laila Woc-Colburn
Laila Woc-Colburn
Division of Infectious Diseases, Emory University, Atlanta, Georgia;
Search for other papers by Laila Woc-Colburn in
Current site
Google Scholar
PubMed
Search for other papers by Laila Woc-Colburn in
Current site
Google Scholar
PubMed
Salvador Villalpando-Carrión
Salvador Villalpando-Carrión
Hospital Infantil de México, Ciudad de México, Mexico;
Search for other papers by Salvador Villalpando-Carrión in
Current site
Google Scholar
PubMed
Search for other papers by Salvador Villalpando-Carrión in
Current site
Google Scholar
PubMed
Daniel B. Chastain
Daniel B. Chastain
Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Albany, Georgia;
Search for other papers by Daniel B. Chastain in
Current site
Google Scholar
PubMed
Search for other papers by Daniel B. Chastain in
Current site
Google Scholar
PubMed
Anis Rassi Jr.
Anis Rassi Jr.
Division of Cardiology, Anis Rassi Hospital, Goiânia, Brazil
Search for other papers by Anis Rassi Jr. in
Current site
Google Scholar
PubMed
Search for other papers by Anis Rassi Jr. in
Current site
Google Scholar
PubMed
ABSTRACT.
Chagas disease affects approximately 300,000 patients in the United States. We evaluated a multicenter U.S.-based network to obtain clinical characteristics and outcomes of chronic Chagas disease by disease forms. This was a U.S.-based, multicenter, population-based, retrospective cohort study. We queried TriNetX, a global research network, to identify patients with dual-positive IgG serology for Trypanosoma cruzi. We captured outcomes of interest for up to 5 years. We found 429 patients with evidence of dual-positive T. cruzi IgG out of 19,831 patients with an available test result from 31 U.S. medical centers. The positive proportion for those tested was 2.2%, up to 4.6% among Hispanics. We found a prevalence of a positive Chagas serology of 0.02% among Hispanics. Cardiomyopathy risk reached an annual rate of 1.3% during the initial 5 years of follow-up among patients with the indeterminate form. We found no new events for pulmonary embolism, sudden death, or left ventricular aneurysms at 5 years. Annual risks for arrhythmias and stroke for chronic Chagas cardiomyopathy (CCC) were 1.6% and 0.8%, respectively. The yearly mortality and hospitalization rates for CCC were 2.7% and 17.1%, respectively. Only 13 patients had a documented antitrypanosomal therapy course within 6 months after diagnosis. Of those receiving treatment, 10 patients received benznidazole and three nifurtimox. Chagas disease screening in patients from endemic areas living in the United States remains crucial. Chronic Chagas cardiomyopathy carries a considerable disease burden, translating into increased morbidity and mortality and an enlarging medical health service utilization.
- Supplemental Materials (PDF 435.02 KB)
Author Notes
Because this study used only de-identified patient records and did not involve collecting, using, or transmitting individually identifiable data, this study was exempted from Institutional Review Board approval. The current project is in HIPAA compliance, according to the Colorado Multiple Institutional Review Board at the University of Colorado Denver (Protocol 19-2011).
Authors’ addresses: Andrés F. Henao-Martínez and Carolina Ferraz, Division of Infectious Diseases, Department of Medicine, University of Colorado Denver, Aurora, CO, E-mails: andres.henaomartinez@cuanschutz.edu and cferraz.carolina@gmail.com. Christian Olivo Freites, Ryan Health, Infectious Diseases, New York, NY, E-mail: christianolivofreites@gmail.com. Nelson I. Agudelo Higuita, Department of Medicine, Section of Infectious Diseases, University of Oklahoma Health Sciences Center, Oklahoma City, OK, and Instituto Antonio Vidal, Tegucigalpa, Honduras, E-mail: nelson-agudelo-higuita@ouhsc.edu. Carlos Franco-Paredes, Hospital Infantil de México, Ciudad de México, Mexico, and Instituto Conmemorativo Gorgas de Estudios de la Salud, Panama City, Panama, E-mail: carlos.franco.paredes@gmail.com. Jose Tuells, Department of Community Nursing, Preventive Medicine and Public Health and History of Science, University of Alicante, Alicante, Spain, E-mail: tuells@ua.es. Laila Woc-Colburn, Division of Infectious Diseases, Emory University, Atlanta, GA, E-mail: laila.eugenia.woc-colburn@emory.edu. Salvador Villalpando-Carrión, Hospital Infantil de México, Ciudad de México, Mexico, E-mail: villalpandoca@himfg.edu.mx. Daniel B. Chastain, Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Albany, GA, E-mail: daniel.chastain@uga.edu. Anis Rassi Jr., Division of Cardiology, Anis Rassi Hospital, Goiânia, Brazil, E-mail: arassijr@terra.com.br.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Rassi A Jr., Rassi A, Marin-Neto JA, 2010. Chagas disease. Lancet 375: 1388–1402.
-
2.
Marcus R, Henao-Martínez AF, Nolan M, Livingston E, Klotz SA, Gilman RH, Miranda-Schaeubinger M, Meymandi S, 2021. Recognition and screening for chagas disease in the USA. Ther Adv Infect Dis 8: 20499361211046086.
-
3.
Irish A, Whitman JD, Clark EH, Marcus R, Bern C, 2022. Updated estimates and mapping for prevalence of Chagas disease among adults, United States. Emerg Infect Dis 28: 1313–1320.
-
4.
Zamora LE, Palacio F, Kozlowski DS, Doraivelu K, Dude CM, Jamieson DJ, Haddad LB, 2020. Chagas disease screening using point-of-care testing in an at-risk obstetric population. Am J Trop Med Hyg 104: 959–963.
-
5.
Hyson P et al., 2021. Experiences with diagnosis and treatment of Chagas disease at a United States teaching hospital–clinical features of patients with positive screening serologic testing. Trop Med Infect Dis 6: 93.
-
6.
Park S, Sanchez DR, Traina MI, Bradfield JS, Hernandez S, Ufion AJA, Dufani J, Bergin P, Wachsner RY, Meymandi SK, 2017. The prevalence of Chagas disease among Latin American immigrants with pacemakers in Los Angeles, California. Am J Trop Med Hyg 96: 1139–1142.
-
7.
Meymandi SK, Forsyth CJ, Soverow J, Hernandez S, Sanchez D, Montgomery SP, Traina M, 2017. Prevalence of Chagas disease in the Latin American-born population of Los Angeles. Clin Infect Dis 64: 1182–1188.
-
8.
Traina MI et al., 2017. Prevalence of Chagas disease in a U.S. population of Latin American immigrants with conduction abnormalities on electrocardiogram. PLoS Negl Trop Dis 11: e0005244.
-
9.
Chadalawada S et al., 2020. Risk of chronic cardiomyopathy among patients with the acute phase or indeterminate form of Chagas disease: a systematic review and meta-analysis. JAMA Netw Open 3: e2015072.
-
10.
Chadalawada S et al., 2021. Mortality risk in chronic Chagas cardiomyopathy: a systematic review and meta-analysis. ESC Heart Fail 8: 5466–5481.
-
11.
Vargas Barahona L et al., 2023. Previous corticosteroid exposure associates with an increased Pneumocystis jirovecii pneumonia mortality among HIV-negative patients: a global research network with a follow-up multicenter case-control study. Ther Adv Infect Dis 10: 20499361231159481.
-
12.
Chastain DB, Motoa G, Ortiz-Martínez Y, Gharamti A, Henao-Martínez AF, 2023. Characteristics and clinical manifestations of monkeypox among people with and without HIV in the United States: a retrospective cohort. AIDS 37: 611–616.
-
13.
Kennis M et al., 2022. Seasonal variations and risk factors of Streptococcus pyogenes infection: a multicenter research network study. Ther Adv Infect Dis 9: 20499361221132101.
-
14.
GovInfo The Health Insurance Portability and Accountability Act of 1996. Public Law 104–191. Available at: https://www.govinfo.gov/app/details/PLAW-104publ191. Accessed August 18, 2023.
-
15.
World Health Organization , 2018. Guidelines for the Diagnosis and Treatment of Chagas Disease. Available at: https://www.who.int/publications/i/item/9789275120439. Accessed July 19, 2023.
-
16.
Pentima MCD, Hwang L-Y, Skeeter CM, Edwards MS, 1999. Prevalence of antibody to Trypanosoma cruzi in pregnant Hispanic women in Houston. Clin Infect Dis 28: 1281–1285.
-
17.
Leiby DA, Herron RM Jr., Read EJ, Lenes BA, Stumpf RJ, 2002. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 42: 549–555.
-
18.
Centers for Disease Control and Prevention , 2007. Blood donor screening for Chagas disease – United States, 2006–2007. MMWR Morb Mortal Wkly Rep 56: 141–143.
-
19.
Hasslocher-Moreno AM, Xavier SS, Saraiva RM, de Sousa AS, 2021. Indeterminate form of Chagas disease: historical, conceptual, clinical, and prognostic aspects. Rev Soc Bras Med Trop 54: e02542021.
-
20.
Rabelo DR, da Costa Rocha MO, de Barros MVL, da Silva JLP, Tan TC, Nunes MCP, 2014. Impaired coronary flow reserve in patients with indeterminate form of Chagas’ disease. Echocardiography 31: 67–73.
-
21.
Olivo Freites C, Sy H, Gharamti A, Higuita NIA, Franco-Paredes C, Suárez JA, Henao-Martínez AF, 2022. Chronic Chagas disease – the potential role of reinfections in cardiomyopathy pathogenesis. Curr Heart Fail Rep 19: 279–289.
-
22.
Moreira HT, Volpe GJ, Mesquita GM, Braggion-Santos MF, Pazin-Filho A, Marin-Neto JA, Schmidt A, 2022. Association of left ventricular abnormalities with incident cerebrovascular events and sources of thromboembolism in patients with chronic Chagas cardiomyopathy. J Cardiovasc Magn Reson 24: 52.
-
23.
Healy C, Viles-Gonzalez JF, Sáenz LC, Soto M, Ramírez JD, d’Avila A, 2015. Arrhythmias in chagasic cardiomyopathy. Card Electrophysiol Clin 7: 251–268.
-
24.
Singh A, Cohen B, Sturzoiu T, Vallabhaneni S, Shirani J, 2020. Recent trends in hospital admissions and outcomes of cardiac Chagas disease in the United States. Int J Crit Illn Inj Sci 10: 134–139.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 6027 | 1815 | 144 |
| Full Text Views | 391 | 91 | 2 |
| PDF Downloads | 239 | 73 | 0 |